Cisco's Fiscal 1Q18 Earnings Beat Analyst Estimates

The US-based (SPY) tech (QQQ) heavyweight Cisco (CSCO) announced its fiscal 1Q18 results on November 15 and reported revenue of $12.1 billion.

Walmart Stock Soared 10.9% on Stellar 3Q Results

Walmart (WMT) stock rose 10.9% to $99.62 after the company reported better-than-expected fiscal 3Q18 results on Thursday, November 16, 2017. Several analysts raised their price targets on the stock.

Home Depot Raised 2017 Guidance after Strong 3Q17 Earnings

Home Depot (HD) posted adjusted EPS of $1.87 on revenues of $25.0 billion. Compared to 3Q16, the company’s EPS rose 16.9%, while revenues rose 8.1%.

Pre-Market Report: Global Markets Are Mixed on November 17

On November 17, the Shanghai Composite Index fell 0.48% and closed the day at 3,382.91. The SPDR S&P China (GXC) rose 1.8% on November 16.


Inside JNJ's Medical Device Business: Developments, Future Growth

In 3Q17, Johnson & Johnson (JNJ) reported ~$19.7 billion in sales. The company’s Medical Devices business generated ~33.5% of the total sales.

Edwards LifeSciences: Here's What's Going On in November 2017

In 3Q17, Edwards Lifesciences (EW) reported adjusted sales of ~$838 million, which is an underlying growth of ~13% on a YoY basis. This performance was driven by double-digit organic growth.

Who's Watching Endo International in 2017?

Of the 21 analysts covering Endo in November 2017, six recommend a “buy” for the stock, while 14 recommend a “hold,” and one recommends a “sell.”

What's Driving AstraZeneca's Valuation after 3Q17 Results?

In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.

What’s Next for Antares Pharma after the FDA Rejection of Xyosted?

Antares Pharma’s (ATRS) products include Vibex, a pressure-assisted autoinjector. The global injectable drug delivery market is expected to grow to $624.5 billion by 2021.

This Week's Movers in Upstream and Oilfield Services

So far this week (starting November 13, 2017), natural gas (UNG) (BOIL) prices are leading a decline in energy commodities.

Where Is Novartis Positioned after 3Q17?

In 3Q17, Novartis (NVS) reported revenues of ~$12.4 billion, which was ~2% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

Where Sanofi Stands after the 3Q17 Results

Sanofi’s 3Q17 earnings were released on November 2, 2017. It reported revenues of 9.05 billion euros for 3Q17, an operational growth of 4.7% YoY.

Part 1
What Investors Can Expect from PetMed Express in 2017

Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.

Who's Thanking Align Technology This November?

In 3Q17, Align Technology reported total revenues close to $385.3 million, which represents YoY growth of ~38.3% and QoQ growth of ~8.1%.

Can Zimmer Biomet Recover after Disappointing 3Q17?

Zimmer Biomet Holdings (ZBH) reported sales of approximately $1.8 billion in 3Q17, which ended on September 30, 2017. The company released its 3Q17 results on November 1, 2017.

Key Takeaways from CVS Health’s 3Q17 Earnings

The Rhode Island–based CVS Health (CVS) reported its results for 3Q17 on Monday, November 6. The results relate to the three-month period that ended on September 30, 2017.

How Is Celgene Positioned after Its 3Q17 Earnings?

In 3Q17, Celgene (CELG) generated revenues of $3.3 billion, which reflected ~10.0% growth year-over-year. Celgene reported an operating margin of ~59.5%.

The Truth behind Pfizer's 3Q17 Earnings

Pfizer (PFE) released its 3Q17 earnings on October 31, 2017, reporting another strong quarter in its Innovative Health business, with a 1% growth in revenues.

How Roche Is Positioned after 3Q17

In 3Q17, Roche Holding (RHHBY) generated revenues of 13.1 billion Swiss francs, which was a ~5% rise YoY. Revenues for its Pharmaceuticals segment rose ~4%, and its Diagnostics segment rose ~6%.

What Drives Sarepta Therapeutics' Growth

In this series, we’ll look at some key growth drivers for Sarepta Therapeutics.

Bristol-Myers Squibb’s Valuation after Its 3Q17 Earnings

Bristol-Myers Squibb’s (BMY) product portfolio includes drugs from various therapeutic areas including Cardiovascular, Virology, Immunoscience, Neuroscience, and Oncology. The chart below shows the revenues of Bristol-Myers Squibb since 4Q15. Because…

What to Expect from Sanofi’s 3Q17 Earnings

Analysts estimate that Sanofi’s gross profit margin will fall 1.2% to 70.6% during 3Q17 as compared to its gross profit margin of 71.8% during 3Q16.

How Amgen Performed in 3Q17

In 3Q17, Amgen (AMGN) generated revenues of around $5.8 billion, a ~1% decline on a year-over-year (or YoY) basis and a ~1% decline on a quarter-over-quarter basis.

Sarepta Therapetics in 2017: Should Investors Be Interested?

On September 19, 2016, Sarepta Therapeutics’ (SRPT) Exondys 51 got approval from the FDA as a therapy for Duchenne muscular dystrophy in patients with a mutation in the dystrophin gene that is amenable to exon 51 skipping.


Please select a profession that best describes you: